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Abstract
Aims In hypertrophy and heart failure, the proarrhythmic persistent Na+ current (INaL) is enhanced. We aimed to investigate
the electrophysiological role of neuronal sodium channel NaV1.8 in human hypertrophied myocardium.
Methods and results Myocardial tissue of 24 patients suffering from symptomatic severe aortic stenosis and concomitant
signiﬁcant afterload-induced hypertrophy with preserved ejection fraction was used and compared with 12 healthy controls.
We performed quantitative real-time PCR and western blot and detected a signiﬁcant up-regulation of NaV1.8 mRNA (2.34-
fold) and protein expression (1.96-fold) in human hypertrophied myocardium compared with healthy hearts. Interestingly,
NaV1.5 protein expression was signiﬁcantly reduced in parallel (0.60-fold). Using whole-cell patch-clamp technique, we found
that the prominent INaL was signiﬁcantly reduced after addition of novel NaV1.8-speciﬁc blockers either A-803467 (30 nM) or
PF-01247324 (1 μM) in human hypertrophic cardiomyocytes. This clearly demonstrates the relevant contribution of NaV1.8 to
this proarrhythmic current. We observed a signiﬁcant action potential duration shortening and performed confocal micros-
copy, demonstrating a 50% decrease in proarrhythmic diastolic sarcoplasmic reticulum (SR)-Ca2+ leak and SR-Ca2+ spark
frequency after exposure to both NaV1.8 inhibitors.
Conclusions We show for the ﬁrst time that the neuronal sodium channel NaV1.8 is up-regulated on mRNA and protein level
in the human hypertrophied myocardium. Furthermore, inhibition of NaV1.8 reduced augmented INaL, abbreviated the action
potential duration, and decreased the SR-Ca2+ leak. The ﬁndings of our study suggest that NaV1.8 could be a promising anti-
arrhythmic therapeutic target and merits further investigation.
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Introduction
Left ventricular remodelling caused by pressure overload
can lead to myocardial hypertrophy. Left ventricular hyper-
trophy (LVH) is an adaptive response to increased chronic
workload and a very common clinical ﬁnding.1,2 It has been
reported that LVH can potentially increase the incidents of
congestive heart failure (HF) and sudden cardiac death.3,4
Furthermore, it has been shown that structural modiﬁcations
due to LVH are associated with HF with preserved ejection
fraction (HFpEF).5 LVH is also associated with an increased
prevalence of cardiac arrhythmias and constitutes an impor-
tant risk factor for cardiac morbidity and mortality.6–9
The pathology of LVH shows not only mechanical but also
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extensive cellular and molecular remodelling including
cardiomyocyte growth changes, dysfunction of excitation–
contraction coupling, certain metabolic dysfunctions, and
ﬁbrosis.10,11
Patients with severe aortic stenosis-dependent symptoms
have a tremendous risk of sudden cardiac death if only
medically treated.12 In the past few decades, a great progress
has been made in underpinning the cellular and molecular
mechanisms of remodelling in myocardial hypertrophy.
However, the involvement of voltage-gated sodium channel
(NaV) isoforms in HFpEF and/or myocardial hypertrophy with
preserved ejection fraction leading to cardiac arrhythmias
has not been elucidated comprehensively. Besides the
peak sodium current causing the action potential (AP) up-
stroke, a small persistent sodium current is existing, also
known as late sodium current (INaL).
13 In case of cardiac
pathology, some INaL producing NaV channels reopen or
remain active throughout the whole AP. The amplitude of INaL
is smaller when compared with peak sodium current but
eventually with a larger Na integral due to longer persistence
during the course of the AP plateau.14 INaL has been reported
to be enhanced in different clinically relevant cardiac pathol-
ogies like hypoxia, ischaemia, and HF.15–17 In severe myocar-
dial hypertrophy, INaL is also enhanced
18 and may cause
intracellular Na+ overload and prolongation of the action
potential duration (APD).19 Consequently, the resulting
Na+ accumulation may lead to intracellular Ca2+ overload
because of reduced efﬂux and increased inﬂux of Ca2+
through Na+/Ca2+ exchanger.20,21
The voltage-gated sodium channel 1.5 (NaV1.5) is consid-
ered the predominant cardiac NaV isoform in the heart.
In the past few years, different reports suggested the
existence of other non-cardiac sodium channels including
NaV1.8 (SCN10A) in the heart, which like NaV1.5 is tetrodo-
toxin resistant. In addition, genetic variants of SCN10A have
been recently shown to inﬂuence cardiac conduction.22,23
Further evidence about NaV1.8 in cardiac conduction
comes from genome-wide association studies reporting
that NaV1.8 could modulate cardiac conduction by effecting
PR and QRS intervals.23 However, the expression of NaV1.8
in cardiac tissue and its direct involvement in human cardiac
arrhythmias is still poorly understood. In the current study,
we investigated the presence and the functional role of
NaV1.8 in cardiac hypertrophy with preserved contractility
derived exclusively from patients suffering from severe
aortic stenosis. To study the role of NaV1.8 channel in the
electrophysiological context of human LVH, we used two
different NaV1.8 blockers, which are described to be very
speciﬁc for NaV1.8 (A-803467 and PF-01247324). The blocker
A-803467 is over 100-fold more selective for the NaV1.8
channel vs. other human NaV channels.
24 Similarly, the
drugPF-01247324 is a highly speciﬁc inhibitor of NaV1.8
over other NaV channels, even when used at very high
concentration.25
Materials and methods
Human myocardial tissue
All procedures were conducted in compliance with the local
ethics committee. The study conforms to the World Medical
Association declaration of Helsinki. Written informed consent
was received from all patients prior to inclusion. Myocardial
tissue of the hypertrophied left ventricle was obtained from
patients (n = 24; Table 1) with severe aortic valve stenosis
and preserved ejection fraction undergoing an open-heart sur-
gery for aortic valve replacement as a classic myectomy (Mor-
row resection). For molecular purposes, we utilized healthy
left ventricular myocardium (n = 12) from healthy donor hearts
that were not transplanted because of technical reasons.
Western blots
Myocardial tissue samples from patients with LVH (n = 12)
compared with healthy control myocardium were homoge-
nized in Tris buffer (pH 7.4) containing Tris–HCl (20 mM), NaCl
(200 mM), NaF (20 mM), Na3VO4 (1 mM), dithiothreitol
(1 mM), Triton X-100 (1%), and complete protease and
phosphatase inhibitor cocktails (Roche Diagnostics, Germany).
Protein concentration was determined by bicinchoninic acid
assay (Pierce Biotechnology, United States). Denatured tissue
homogenates (10 min, 70°C in 2% beta-mercaptoethanol)
were separated on 7.5% sodium dodecyl sulfate–
polyacrylamide gels, then transferred to a nitrocellulose mem-
brane, and incubated with the following primary antibodies:
mouse monoclonal anti-NaV1.8 (1:1000, LSBio, United States,
LS-C109037), rabbit polyclonal anti-NaV1.5 (1:2000, Alomone
Labs, Israel, ASC-005), and mouse monoclonal anti-GAPDH
(1:20000, Biotrend, Germany, BTMC-A473-9) at 4°C overnight.
Table 1 Patient characteristics: values in the table represent the
mean ± standard error of the mean
Male sex 50%
Age 66.38 ± 3.66 years
Ejection fraction 56.95 ± 1.81%
Dyspnoea 85.7%
Interventricular septum 15.0 ± 1.7 mm
Aortic valve area 0.8 ± 0.1 cm2
Mean AV pressure gradient 44 ± 6.4 mm Hg
Diabetes 4.3%
ACE-inhibitors 17.4%
β-Blockers 65.2%
Diuretics 76.5%
Digoxin 0.0%
Amiodarone 0.0%
AT1 receptor antagonists 26.1%
Aldosterone antagonists 0.0%
Statins 30.4%
Ca channel blockers 26.1%
ACE, angiotensin-converting enzyme; AT1, angiotensin II receptor–
type 1; AV, aortic valve.
2 S. Ahmad et al.
ESC Heart Failure (2018)
DOI: 10.1002/ehf2.12378
Secondary antibodies included horseradish peroxidase (HRP)-
conjugated goat anti-rabbit and goat anti-mouse (1:10000,
Jackson ImmunoResearch, United Kingdom, 111-035-144 and
115-035-062, respectively). The membrane was incubated with
secondary antibodies for 1 h at room temperature. Immobilon™
Western Chemiluminescent HRP Substrate (Millipore, Germany)
was used for the chemiluminescent detection.
Quantitative real-time PCR
Human cardiac tissues were snap-frozen in liquid nitrogen and
stored at 80°C. RNA was isolated by use of the SV Total RNA
Isolation System (Promega, Germany). DNA standards were
generated by serial dilution in diethyl pyrocarbonate water
containing yeast tRNA (30 μL/mL) as co-precipitant and used
at varying concentrations between 0.125 and 100 000 fg/μL
to ensure exponential growth of DNA amounts in the standard
range. One hundred nanogram of RNAwas reverse transcribed
into cDNA using standard protocols. For quantitative PCR,
10 μL of SYBR Green PCR Master Mix (Thermo Fisher,
Germany), 7 μL of nuclease-free water, 1 μL of forward and
1 μL of reverse primer, and 1 μL of cDNA were mixed.
Quantitative PCR was carried out using the iQ5 Multicolor
Real-time PCR Detection System (Bio-Rad, United States). Forty
cycles of 15 s at 95°C followed by 1 min at 60°C were used,
and ﬂuorescence was measured after each cycle. After 40 cycles,
melt curve analysis was performed to ensure speciﬁcity of the
products. Thresholds cycles were evaluated and normalized to
housekeeping genes and controls. The following primer se-
quences (50-30) were used for quantitative real-time PCR analy-
ses: SCN10A, forward TGGCAGATGACCTGGAAGAACC and
reverse CGATACGGTAGCAAGTCTTGCG (Origene, Cat. no.
HP209444, NM_006514); and GAPDH, forward GTCTCCTCTGA
CTTCAACAGCG and reverse ACCACCCTGTTGCTGTAGCCAA.
Myocyte isolation
Left ventricular myocardium was rinsed, cut into small
pieces, and incubated at 37°C in a spinner ﬂask ﬁlled with
Joklik-MEM (JMEM) solution (PAN-Biotech, Germany) that
contained 1.0 mg/mL collagenase (Worthington type 1,
185 U/mg, CellSystems, France) and 13% trypsin (Life Tech-
nologies, United States). After 45 min, the supernatant was
discarded, and fresh JMEM solution containing collagenase
was added. The solution was incubated for 10 min until
myocytes were disaggregated. The supernatant that
contained disaggregated cells was removed and centrifuged
(700 rpm, 5 min).
Fresh JMEM with collagenase was added to the remaining
tissue. This procedure was repeated four to ﬁve times. After
every step, the centrifuged cells were resuspended in JMEM
solution that contained bovine calf serum 10%, and pH was
adjusted to 7.4 at room temperature. Only cell solutions that
contained elongated, not granulated, cardiomyocytes with
cross-striations were selected for experiments, plated on
laminin-coated recording chambers, and left to settle for 30 min.
Whole-cell patch clamp
INaL measurements
Ruptured-patch whole-cell voltage-clamp was used to mea-
sure INaL in human ventricular cardiomyocytes isolated from
hypertrophied hearts with microelectrodes (2–3 MΩ).
Pipettes were ﬁlled with solution containing CsCl (95 mM),
Cs-glutamate (40 mM), NaCl (10 mM), MgCl2 (0.92 mM),
Mg-ATP (5 mM), Li-GTP (0.3 mM), HEPES (5 mM), niﬂumic
acid (0.03 mM; to block Ca2+-activated chloride current),
nifedipine (0.02 mM; to block Ca2+ current), strophanthidin
(0.004 mM; to block Na+/K+-ATPase), EGTA (1 mM), and CaCl2
(0.36 mM; free [Ca2+]i, 100 nM), and pH was adjusted to 7.2
with CsOH. The bath solution contained NaCl (135 mM),
tetramethylammonium chloride (5 mM), CsCl (4 mM), MgCl2
(2 mM), glucose (10 mM), and HEPES (10 mM), and pH
was adjusted to 7.4 with CsOH. To minimize contaminating
Ca2+ currents during INaL measurements, Ca
2+ was omitted
from the bath solution. Access resistance was <7 MΩ.
Cardiomyocytes were held at 120 mV, and INaL was elicited
using a train of pulses to 35 mV (1000 ms duration, 10
pulses, basic cycle length 2 s). Recordings were initiated
3 min after rupture. The measured INaL at 35 mV was leak
subtracted before calculation of the INaL integral (between
100 and 500 ms) and was normalized to membrane capaci-
tance of the measured cell. Cardiomyocytes were treated
with either A-803467 (30 nM) or PF-01247324 (1 μM) for
10 min and compared with the control untreated cells. Mea-
surements were conducted at a temperature of 37.7°C.
Action potential duration measurements
To record the AP from human ventricular cardiomyocytes,
the whole-cell patch-clamp technique was used to measure
membrane potential (current clamp conﬁguration). Micro-
electrodes (7–8 MΩ) were ﬁlled with solution containing
K-Aspartate (92 mM), KCl (48 mM), Mg-ATP (1 mM), HEPES
(10 mM), EGTA (0.02 mM), GTP-Tris (0.1 mM), and Na2-ATP
(4 mM), and ﬁnal pH was adjusted at 7.2 with KOH solution.
Bath solution contained NaCl (140 mM), KCl (4 mM), MgCl2
(1 mM), CaCl2 (2 mM), glucose (10 mM), and HEPES
(10 mM), and ﬁnal pH was adjusted to 7.4 with NaOH. Action
potentials were continuously elicited by square current
pulses of 1–2 nA amplitude and 1–5 ms duration at increasing
stimulation frequency (0.5–3 Hz). Access resistance was
typically ~5–15 MΩ after patch rupture. Fast capacitance
was compensated for in a cell-attached conﬁguration.
Recordings were commenced after cell stabilization, which
was ~10 min after rupture. Human cell measurements were
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conducted at a temperature of 37.7°C. Every cell was patched
and measured before and after drug application.
In all patch-clamp experiments, cardiomyocytes were
mounted on the stage of a microscope (Nikon T 300).
Fast capacitance was compensated in cell-attached conﬁgura-
tion. Membrane capacitance and series resistance were com-
pensated after patch rupture. Signals were ﬁltered with 2.9
and 10 kHz Bessel ﬁlters and recorded with an EPC10
ampliﬁer (HEKA Elektronik, Germany). NaV1.8 was inhibited
using either A-803467 (30 nM for 10 min) or PF-01247324
(1 μM for 5 min). Both drugs were added to the bath solution.
Measurement of Ca2+ sparks
Isolated cardiomyocytes were incubated at room temperature
for 30 min with a Fluo-4 AM loading buffer (10 μM; Molecular
Probes, Life Technologies). Experimental solution contained
NaCl (136 mM), KCl (4 mM), NaH2PO4 (0.33 mM), NaHCO3
(4 mM), CaCl2 (2 mM), MgCl2 (1.6 mM), HEPES (10 mM), and
glucose (10 mM), and ﬁnal pH was adjusted to 7.4 by addition
of NaOH solution at room temperature. NaV1.8 inhibitors
A-803467 (30 nM) and PF-01247324 (1 μM) were added to
their respective groups in the experimental solution.
Cells were continuously superfused during experiments. To
wash out the loading buffer and to remove any extracellular
dye (as well as to provide enough time for complete
de-esteriﬁcation of Fluo-4 AM), cells were superfused with
experimental solution for 5 min before the experiments were
begun. Ca2+ spark measurements were performed with a
laser scanning confocal microscope (LSM 5 Pascal, Zeiss,
Germany) using a ×40 oil-immersion objective. Fluo-4 was ex-
cited by an argon ion laser (488 nm), and emitted ﬂuores-
cence was collected through a 505 nm long-pass mission
ﬁlter. Fluorescence images were recorded in the line scan
mode with 512 pixels per line (width of each scan line:
38.4 μm) and a pixel time of 0.64 μs. One image consists of
10 000 unidirectional line scans, which equates to a measure-
ment period of 7.68 s. Experiments were conducted at resting
conditions after the sarcoplasmic reticulum (SR) was loaded
with Ca2+ by repetitive ﬁeld stimulation (10 pulses at 1 Hz,
20 V). Ca2+ sparks were analysed with the program
SparkMaster for ImageJ. The mean spark frequency of the
respective cell resulted from the number of sparks normal-
ized to cell width and scan rate (100 μm1 s1).
Results
Regulation of NaV1.5 and NaV1.8 in human left
ventricular hypertrophy
To investigate the regulation of NaV1.8 and NaV1.5 protein
expression in human LVH compared with healthy control
ventricular myocardium tissue homogenates, western
Figure 1 Regulation of NaV1.8 and NaV1.5 expression in hypertrophy. (A) Western blots were performed utilizing left ventricular human tissue homog-
enates. (B) Densitometry data of NaV1.8 and NaV1.5 show a signiﬁcant up-regulation of NaV1.8 and down-regulation of NaV1.5. GAPDH was used as an
internal loading control in all blots [NF: n = 12; and left ventricular hypertrophy (LVH): n = 12]. (C) Real-time quantitative PCR showing the relative
mRNA expression of NaV1.8/GAPDH in left ventricle of human NF (n = 10) and LVH (n = 5). *P ≤ 0.05 and **P ≤ 0.01 vs. NF. Student’s t-test. Data shown
as mean ± standard error of the mean and individual values.
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blots were performed. We found a signiﬁcant up-regulation of
NaV1.8 protein expression (1.96- ± 0.31-fold) in LVH compared
with healthy control ventricular myocardium (Figure 1B). In
contrast, the expression of NaV1.5 protein was signiﬁcantly
decreased (0.60- ± 0.10-fold) compared with Non-failing (NF)
(Figure 1B). In accordance to our ﬁndings of NaV1.8
expression at the protein level, we recorded a signiﬁcant up-
regulation of NaV1.8 mRNA levels in LVH (2.34- ± 0.64-fold,
n = 5) compared with NF (n = 10) by quantitative PCR. The
mRNA expression of NaV1.8 is shown as relative expression to
the housekeeping gene GAPDH (Figure 1C).
NaV1.8 contributes to INaL and action potential
duration in human hypertrophy
Given the increased expression of NaV1.8 in human LVH, we in-
vestigated the potential contribution to the augmentation of INaL
and APD prolongation under hypertrophic condition. We
adopted the approach using novel-speciﬁc blockers of NaV1.8
channel A-803467 and PF-01247324 to inhibit the activity of this
channel in human LVH cardiomyocytes for recording INaL and
APDs by patch clamp. Cardiomyocytes were superfused with
either A-803467 or PF-01247324. Our data show a signiﬁcant re-
duction in INaL (Figure 2) and also shortening of APD90 (Figure 3)
when cardiomyocytes were exposed to NaV1.8 inhibitors
compared with the control group. Furthermore, both NaV1.8
inhibitors do not exert any effect on the upstroke velocity and
amplitude of the AP (Figure 4A and 4B). Therefore, it can be
concluded that NaV1.8 contributes to INaL in terms of a positive
net inward current to APD prolongation in human hypertrophy.
Contribution of NaV1.8 to proarrhythmic SR-Ca
2+
leak
During pathological conditions such as HF, an enhanced INaL
can lead to disturbed SR-Ca2+ metabolism and hence
potentially proarrhythmic SR-Ca2+ leakiness. This can give rise
to delayed after-depolarizations and thereby arrhythmias.
However, the contribution of different NaV isoforms to SR-
Ca2+ leak in human LVH has not been evaluated. Therefore,
we measured SR-Ca2+ leak in isolated cardiomyocytes from
human hypertrophied hearts.
We detected a high incident of spontaneous diastolic Ca2+
release events in hypertrophied cardiomyocytes in the
absence of inhibitors (Figure 5A). When cardiomyocytes
were incubated with NaV1.8 inhibitors either A-803467 or
PF-01247324, a signiﬁcant decrease in calcium spark
frequency (CaSpF) and SR-Ca2+ leak was observed compared
with control group (Figure 5B and 5E). In control cells,
CaSpF was 0.68 ± 0.12 μm1 s1 (n = 145 cells/12 patients),
while in A-806734-treated myocytes, CaSpF was reduced to
0.27 ± 0.06 μm1 s1 (n = 124 cells/11 patients, P ≤ 0.01)
and in PF-01247324-treatedmyocytes to 0.26 ± 0.07 μm1 s1
(n = 91 cells/9 patients, P ≤ 0.01), respectively (Figure 5B).
NaV1.8 inhibition with PF-01247324 also resulted in a signif-
icant reduction of the Ca2+ spark duration (Figure 5C), while
no differences were recorded for Ca2+ spark amplitude
between control and drug treatment groups (Figure 5D).
These data clearly demonstrate the important role of the
NaV1.8 channel in SR-Ca
2+ leak regulation in hypertrophy.
Taken together, proarrhythmic SR-Ca2+ release can signiﬁ-
cantly be decreased by targeting NaV1.8 with speciﬁc
inhibitors.
Discussion
LVH is a common clinical ﬁnding in daily practice caused,
besides some other reason, by hypertension and aortic valve
stenosis. At the early stages, myocardial hypertrophy serves
as a compensatory mechanism, which can lead to systolic
HF at later stages.26 Importantly, patients with symptomatic
aortic stenosis have a tremendous risk of sudden cardiac
Figure 2 (A) Original traces and (B) data showing individual and mean values ± standard error of the mean of INaL in human ventricular cardiomyocytes
isolated from left ventricular hypertrophy patients (control: n = 8 cells; A-803467: n = 7 cells; PF-01247324: n = 7 cells). *P ≤ 0.05. One-way analysis of
variance and Bonferroni’s post-test.
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death if only medically treated.12 In the past few decades,
a great progress has been made in underpinning the
cellular and molecular mechanisms of remodelling during
hypertrophy. However, the mechanistic links between dysreg-
ulated proteins and in particular arrhythmogenesis, especially
in human hypertrophy, still remain elusive. We herein inves-
tigated the regulation of neuronal sodium channel NaV1.8
and its role in pathophysiology of human signiﬁcant hypertro-
phy. We demonstrate that NaV1.8 expression is up-regulated
during LVH with preserved ejection fraction compared with
healthy left ventricles, while NaV1.5 expression is down-
regulated in parallel. To the best of our knowledge, this is
the ﬁrst report of such an ion channel switch in human
hypertrophy. Furthermore, inhibition of NaV1.8 by speciﬁc
blockers causes a signiﬁcant reduction of the enhanced INaL
and consequently leads to abbreviated APDs in LVH. More-
over, we observed a signiﬁcant decrease of the proarrhythmic
SR-Ca2+ leak by inhibition of NaV1.8 in human hypertrophied
cardiomyocytes. Therefore, inhibition of NaV1.8 modulates
well-accepted proarrhythmogenic triggers such as INaL, APD
prolongation, and diastolic SR-Ca2+ leak.
In the current study, we found increased expression of
NaV1.8 at both mRNA and protein level in human LVH with
preserved contractility when compared with NF. Transcripts
of many non-cardiac NaV channels (NaV1.1, NaV1.3, NaV1.2,
and NaV1.6) including NaV1.8 were detected in mouse and
dog heart, while there was no previous evidence of
NaV1.8 expression in the human ventricle during LVH.
27,28
Moreover, there have been conﬂicting reports about the
involvement of these non-cardiac NaV isoforms in INaL en-
hancement in animal models due to species-speciﬁc expres-
sion. We already reported that the protein expression of
other non-cardiac NaV channels (NaV1.1 and NaV1.6) was
down-regulated while NaV1.5 was increased showing no
signiﬁcant INaL enhancement in a transverse aortic constric-
tion mouse model of compensated hypertrophy.17 Similar
ﬁndings were reported in a dog and rat HF model where
NaV1.5 protein expression was found to be down-regulated,
whereas a signiﬁcant increase in INaL was observed.
29,30
These ﬁndings from animal models suggest the involvement
of other non-cardiac sodium channels in INaL augmentation
and arrhythmogenesis under hypertrophy and HF condi-
tions. However, animal models represent a very artiﬁcial
variability in hypertrophy, which cannot be compared di-
rectly with human hypertrophy with severe aortic stenosis.
Moreover, these animal-derived ﬁndings cannot be directly
translated into the human because of severe differences
in cellular electrophysiology. Therefore, the translational
data of our current study add novel knowledge on INaL
regulation in hypertrophy and show for the ﬁrst time that
INaL augmentation is also caused by over-expression of
NaV1.8 in human hypertrophy.
Electrophysiological recordings also described that non-
cardiac NaV channels contribute to INaL up to 44% in canine
ventricular cardiomyocytes under normal physiological
conditions31 and NaV1.8 was suggested to be a major contrib-
utor of INaL in healthy mouse ventricular cardiomyocytes.
32
However, NaV1.8 was not investigated before in animal models
Figure 3 (A) Original action potential recording (0.5 Hz) and (B) data showing individual and mean values ± standard error of the mean of APD90 in left
ventricular cardiomyocytes from patients with left ventricular hypertrophy. A-803467 or PF-01247324 paced at 0.5 and 1 Hz (n = 5 cells and n = 4 cells,
respectively; *P ≤ 0.05 vs. control). Two-way repeated measures analysis of variance and Bonferroni’s post-test. All the action potential duration (APD)
measurements were performed pairwise by wash-in.
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with present heart disease, for example, hypertrophy. It was
shown previously by us and other groups that increased INaL
is implicated as potential contributor to proarrhythmogenic
triggers and thereby to the occurrence of arrhythmias.33–35
During different pathological conditions associated with heart
diseases, over-expression of these non-cardiac NaV channels
was also shown to be responsible for the prolonged cardiac
APD.31 The functional properties of NaV1.8 are characterized
by a long AP duration with preserved excitability during
sustained stimulation in the dorsal root ganglion.36 In accor-
dance with an enhanced INaL, we observed prolongation of
APD in ventricular cardiomyocytes of hypertrophy patients. In-
hibition of NaV1.8 with speciﬁc blockers showed a signiﬁcant
abbreviation of APD. Up-regulated NaV1.8 expression in
human hypertrophy may cause increased INaL potentially lead-
ing to a pathological prolongation of APD in this disease. This
prolonged APD can give rise to early after-depolarizations,
thereby posing increased fatal risk for ventricular arrhyth-
mias.13 The partial inhibition of INaL up to 50% not only
restored healthy APD in failing cardiomyocytes but also ceased
after-depolarizations.13
Isolated cardiomyocytes from patients with hypertrophic
cardiomyopathy showed an augmented INaL with a subse-
quent increase in intracellular Ca2+ load.18 Enhanced INaL
might lead to diastolic Ca2+ overload through the Na+/Ca2+ ex-
changer operation in reverse mode.37 An increase in diastolic
Ca2+ not only results in impaired relaxation but also plays a
key role in activating pro-hypertrophic signalling pathways,
Figure 4 (A) Individual and mean values ± standard error of the mean showing upstroke velocity of action potential in control and drug groups from
left ventricular hypertrophy cardiomyocytes. (B) Data showing individual and mean values ± standard error of the mean of action potential amplitude
(APA) measurements from isolated human left ventricular hypertrophy cardiomyocytes. (C) Graph shows the resting membrane potential (RMP) of
cardiomyocytes measured under control condition and drug treatments (PF-01247324: n = 5 cells; and A-804367: n = 4 cells). All measurements were
performed pairwise by wash-in. Paired Student’s t-test was performed.
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leading to increased stiffness of the left ventricle.38,39 These
data suggest that INaL is not only the consequence
of hypertrophy but is also involved in inducing
diastolic intracellular Ca2+ overload. The resulting Ca2+ load is
thought to trigger intracellular spontaneous Ca2+-release
events, leading to cytosolic Ca2+ oscillations, automaticity,
and triggered activity. In addition to animal studies, we have
previously demonstrated that inhibition of an enhanced INaL
with tetrodotoxin or ranolazine reduces the SR-Ca2+ leak in
human diseased cardiomyocytes.37,40 In the present study,
we extend this evidence to human cardiomyocytes with
very signiﬁcant hypertrophy and HFpEF. The highly speciﬁc
inhibition of NaV1.8 potently suppressed the diastolic SR-
Ca2+ leak in ventricular cardiomyocytes of patients with severe
LV hypertrophy. Taken together, the data of our present study
deﬁne a signiﬁcant contribution of NaV1.8 in the initiation
of proarrhythmic triggers via INaL-induced SR-Ca
2+ leak and
also APD prolongation. The differences between the activation
of NaV1.5 and NaV1.8 suggest that the selective inhibition
of NaV1.8-mediated INaL can be antiarrhythmic.
Patients with severe aortic stenosis and concomitant LV
hypertrophy including HFpEF are at high risk of sudden
cardiac death, and one of the probable causes is lethal
arrhythmias. Our current study provides better understand-
ing of electrophysiological disturbances that occur in human
severe hypertrophy. We identiﬁed a potential new ion
channel target (NaV1.8) and provide a respective possible
pharmacological antiarrhythmic approach. Therefore, these
ﬁndings provide basic evidence for in vivo studies.
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